Clinical Trials Logo

Endometrial Neoplasms clinical trials

View clinical trials related to Endometrial Neoplasms.

Filter by:

NCT ID: NCT05483023 Recruiting - Endometrial Cancer Clinical Trials

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Start date: February 15, 2024
Phase: Phase 2
Study type: Interventional

Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial Cancer (EC). Participants: Eight women with histologically confirmed CAH or Grade 1 EC who have planned treatment with LR-IUD will be recruited.. Procedures (methods): The is a prospective, single arm, pilot study of 8 participants who will receive one FFNP PET/MRI scan. Medical records will be followed for 6 months.

NCT ID: NCT05481645 Recruiting - Clinical trials for Advanced Endometrial Cancer

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Start date: August 22, 2022
Phase: Phase 2
Study type: Interventional

This study plans to enroll 69 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The experimental set is divided into lead-in trial and formal trial. The lead-in trial includes 9 subjects to observe the safety of the combination and determine the dosage of anlotinib dihydrochloride capsules before the formal phase. The formal trial includes 60 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The purpose is to evaluate efficacy and safety of TQB2450 injection combined with chemotherapy ± anlotinib hydrochloride capsules for first-line treatment and maintenance treatment of patient with advanced endometrial cancer or sarcoma of uterus, and explore biomarkers related to efficacy, mechanism of action, safety and/or pathological mechanisms, the surgical conversion rate. ORR is the primary endpoint.

NCT ID: NCT05454358 Recruiting - Endometrial Cancer Clinical Trials

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

Start date: August 2, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Aim to investigate the effect of Letrozole as maintenance after adjuvant treatment on the prognosis of post-operative endometrial cancer patients with non-specific molecular profile.

NCT ID: NCT05448586 Completed - Breast Cancer Clinical Trials

Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?

Start date: February 2, 2019
Phase:
Study type: Observational

Opioid Free Anesthesia (OFA) is a multimodal anesthesia and emerging technique that spares the use of opioids and involve other adjuvant anesthetics, which have demonstrated in vitro influence on immunologic and inflammatory response, as well as in metastatic progression. For these reasons we believe that OFA may positively influence in oncologic patients postoperative recovery and in its disease progression.

NCT ID: NCT05446324 Recruiting - Endometrial Cancer Clinical Trials

Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer

SENGA
Start date: February 15, 2023
Phase: Phase 3
Study type: Interventional

This pilot study evaluates the feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with endometrial cancer.

NCT ID: NCT05427058 Not yet recruiting - Cervical Cancer Clinical Trials

Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

This study compared the efficacy and safety of superior hypogastric plexus block and ganglion impar block procedures on the management of pelvic and perineal cancer pain in patients with cervical and endometrial cancer

NCT ID: NCT05419817 Withdrawn - Solid Tumors Clinical Trials

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Start date: September 8, 2022
Phase: Phase 2
Study type: Interventional

This is a study of pembrolizumab in combination with sitravatinib in adult women with recurrent endometrial cancer or other solid tumors with deficient mismatch repair system. All patients enrolled will receive pembrolizumab as standard of care combined with Sitravatinib, which will be self-administered orally daily.

NCT ID: NCT05410717 Recruiting - Clinical trials for Stage IV Ovarian Cancer

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)

NCT ID: NCT05407025 Active, not recruiting - Clinical trials for Endometrial Carcinoma

Targeting Inflammation for Endometrial Cancer Prevention

Start date: December 1, 2021
Phase:
Study type: Observational

This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.

NCT ID: NCT05396794 Recruiting - Obesity Clinical Trials

Bariatric Education for Women With Obesity and Endometrial Cancer

SCC-BAREDU
Start date: August 30, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to examine whether a standardized video education tool will improve knowledge regarding obesity and bariatric surgery and increase bariatric surgery referrals for obese women with endometrial cancer.